Report of Foreign Issuer (6-k)
November 03 2016 - 2:13PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November, 2016
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On November 3, 2016, GW Pharmaceuticals plc (the “Company”),
issued a regulatory news service (“RNS”) announcement setting forth details of the conversion by Mr. Christopher Tovey,
the Company’s Chief Operating Officer and a Director of certain of his ordinary shares par value £0.001per share (“Ordinary
Shares”) into American Depositary Shares (“ADSs”). This RNS is attached as Exhibit 99.1 hereto and is incorporated
by reference herein. On November 2, 2016 , the Company issued an RNS with details of the conversion by Mr. Justin Gover, the Company’s
Chief Executive Officer and a Director of certain of his ordinary shares into ADSs. This RNS is attached as Exhibit 99.2 hereto
and is incorporated by reference herein. On November 1, 2016 , the Company issued an RNS with details of the conversion by Mr.
James Noble, a Director, of certain of his ordinary shares into ADSs. This RNS is attached as Exhibit 99.3 hereto and is incorporated
by reference herein. On October 28, 2016, the Company issued a press release with details of the establishment by Dr Geoffrey Guy,
Chairman of the Company’s Board of Directors, of a personal stock trading plan in accordance both with the guidelines established
by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the EU Market Abuse
Regulation, as well as the Company’s policies with respect to insider trading. This press release is attached as Exhibit
99.4 hereto and is incorporated by reference herein. On October 28, 2016 the Company issued an RNS with details of sales of Ordinary
Shares by Dr Geoffrey Guy, Chairman of the Company’s Board of Directors. This RNS is attached as Exhibit 99.5 hereto and
is incorporated by reference herein. The information contained in Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5 hereto shall not be
deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
|
Exhibits
|
|
|
|
99.1
|
|
Regulatory news service announcement dated November 3, 2016 regarding Mr. Christopher Tovey
|
|
99.2
|
|
Regulatory news service announcement dated November 2, 2016 regarding Mr. Justin Gover
|
|
99.3
|
|
Regulatory news service announcement dated November 1, 2016 regarding Mr. James Noble
|
|
99.4
|
|
Press Release dated October 28, 2016 regarding Director Stock Trading Plan
|
|
99.5
|
|
Regulatory news service announcement dated October 28, 2016 regarding Dr Geoffrey Guy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
GW Pharmaceuticals plc
|
|
|
|
|
|
|
By:
|
/s/ Adam George
|
|
|
Name:
|
Adam George
|
|
|
Title:
|
Chief Financial Officer
|
|
|
|
|
|
Date: November 3, 2016
|
|
|